Today's COVID-19 News: January 29, 2021

J&J Announces Single-Shot COVID-19 Vaccine Candidate Met Primary Endpoints

Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. Read more...

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Novavax announced NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). Read more...

Omixon, SeqOnce Announce Extension to AzureSeq-200 Assay to Detect SARS-CoV-2 N501Y Variant

Omixon and SeqOnce Biosciences announce the launch of a new extension to the AzureSeq One-Step Universal RT-qPCR kit for the detection of the novel coronavirus SARS-CoV-2 N501Y variant. Read more...

AstraZeneca COVID-19 Vaccine Recommended for use in the EU

AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorization (CMA) in the European Union (EU) for active immunization to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Read more...

  • <<
  • >>

Comments